LivePerson Surges 22.94% On Q3 Revenue (NASDAQ:LPSN)

LivePerson, Inc. (NASDAQ:LPSN)

As the world turns progressing internet online experiences, I would like to direct your attention to LivePerson, Inc. stock symbol LPSN. LivePerson specializes in cloud-based platform that allows businesses to proactively connect in real-time with their customers. The Company is currently experiencing a surge of  22.94% Up 2.09 with over 1.5 million shares in play at a price of $11.20 per share Thursday, Nov. 7, 2013 2:46PM EST.. So what is prospecting investors in their direction you ask? The answer is revenue (chi-ching).

LivePerson is currently rolling in the dough, with B2B operations running smoothly up 15% Q3 2013 in comparison to last years Q3 2012. The Company’s total revenue which includes consumer operations brought in $45.2 million, while their business segment grew 19% in comparison to 2012. So i would assume that digital engagement is something to look forward to for the future. So who cares if the Company’s cash balance is at $77.4 million as of September 30, 2013 , and up $2.4 million I might add  in comparison to the $75.0 million June 30, 2013. If I had a Company (www.liveperson.com) like this in my portfolio I would be giggling all the way to the bank.

****

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK)

As the Dow struggles at 15,608.01 I figured it would be a great time to observe the return of the MACK. Merrimack Pharmaceuticals, Inc. stock symbol MACK specializes in  bio-pharmaceutical in concern of innovative medicines matched with companion diagnostics for cancer treatment. The Company is currently experiencing a surge of  17.59% Up 0.36 with over 6.8 million shares in play at a price of  $2.42 per share Thursday, Nov. 7, 2013 3:31PM EST.. So what’s so special about this you ask?

Even though the Company had slightly disappointing figures on their Q3 2013 report, MM-398 made up for it. MM-398 is a nanotherapeutic made up of the chemotherapeutic irinotecan, encapsulated in a liposomal sphere. MM-398 therapy is advanced pancreatic cancer drug for the purpose of  is minimizing chemotherapy exposure to non-targets cells. If  I was a shareholder and I’m not, I would assumptionally remain calm as long as the Company (www.merrimackpharma.com) plans to move onward with MM-398 trials. Who cares if they moved back the date a little, when good things comes to those that wait. Need I not forget to mention that MM-121 in combination with paclitaxel met a key study objective.

Remember: Always do your homework and consult your own financial professional.

(Read Full Disclaimer at http://crwewallstreet.com/disclaimer).